The impact of psoriasis on quality of life goes beyond clinical measures, such as psoriasis area severity index (PASI) and body surface area (BSA), a study finds.
The 18-meter walk test (18MWT) effectively evaluates disease severity and predicts clinical outcomes in pulmonary arterial hypertension (PAH), enhancing traditional assessment methods.
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.